Glaukos Corporation – NYSE:GKOS
Glaukos stock price today
$89
-62.16
-41.12%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Glaukos stock price monthly change
+24.83%
month
Glaukos stock price quarterly change
+24.83%
quarter
Glaukos stock price yearly change
+87.85%
year
Glaukos key metrics
Market Cap | 8.17B |
Enterprise value | 2.63B |
P/E | -23.99 |
EV/Sales | 9.30 |
EV/EBITDA | -53.99 |
Price/Sales | 8.37 |
Price/Book | 4.47 |
PEG ratio | 0.25 |
EPS | -2.88 |
Revenue | 326.43M |
EBITDA | -89.66M |
Income | -140.87M |
Revenue Q/Q | 15.86% |
Revenue Y/Y | 12.92% |
Profit margin | -35.07% |
Oper. margin | -36.17% |
Gross margin | 75.61% |
EBIT margin | -36.17% |
EBITDA margin | -27.47% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeGlaukos stock price history
Glaukos stock forecast
Glaukos financial statements
Average Price Target
$147.8
Potential upside: 66.06%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 80.39M | -32.81M | -40.81% |
|---|---|---|---|
| Sep 2023 | 78.04M | -30.44M | -39.01% |
| Dec 2023 | 82.36M | -36.77M | -44.65% |
| Mar 2024 | 85.62M | -40.83M | -47.7% |
| Jun 2023 | 956740000 | 467.92M | 48.91% |
|---|---|---|---|
| Sep 2023 | 948634000 | 470.97M | 49.65% |
| Dec 2023 | 940414000 | 478.64M | 50.9% |
| Mar 2024 | 933338000 | 482.60M | 51.71% |
| Jun 2023 | -8.16M | 25.95M | -880K |
|---|---|---|---|
| Sep 2023 | -8.16M | 14.89M | 7.46M |
| Dec 2023 | -10.66M | -12.92M | 7.30M |
| Mar 2024 | -33.87M | -29.38M | 13.16M |
Glaukos alternative data
| Aug 2023 | 783 |
|---|---|
| Sep 2023 | 783 |
| Oct 2023 | 783 |
| Nov 2023 | 783 |
| Dec 2023 | 783 |
| Jan 2024 | 783 |
| Feb 2024 | 783 |
| Mar 2024 | 907 |
| Apr 2024 | 907 |
| May 2024 | 907 |
| Jun 2024 | 907 |
| Jul 2024 | 907 |
Glaukos other data
45.19%
-52.61%
of GKOS is owned by hedge funds
130
-81
21.43M
-25.12M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 170698 |
| Feb 2024 | 0 | 166781 |
| Mar 2024 | 0 | 13347 |
| Apr 2024 | 0 | 65516 |
| May 2024 | 0 | 16694 |
| Jun 2024 | 0 | 2500 |
| Jul 2024 | 0 | 2250 |
| Aug 2024 | 0 | 36250 |
| Sep 2024 | 0 | 3000 |
| Oct 2024 | 0 | 2275 |
| Dec 2024 | 0 | 15328 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | KLIMAN GILBERT H director | Common Stock | 10,000 | $32 | $320,000 | ||
Option | GILLIAM JOSEPH E officer: PRESIDEN.. | Common Stock | 2,275 | $69.3 | $157,658 | ||
Sale | GILLIAM JOSEPH E officer: PRESIDEN.. | Common Stock | 2,036 | $149.54 | $304,463 | ||
Option | GILLIAM JOSEPH E officer: PRESIDEN.. | Common Stock | 1,053 | $39.1 | $41,172 | ||
Sale | GILLIAM JOSEPH E officer: PRESIDEN.. | Common Stock | 1,292 | $150.35 | $194,252 | ||
Option | GILLIAM JOSEPH E officer: PRESIDEN.. | Stock Option (Right to Buy) | 2,275 | $69.3 | $157,658 | ||
Option | GILLIAM JOSEPH E officer: PRESIDEN.. | Stock Option (Right to Buy) | 1,053 | $39.1 | $41,172 | ||
Sale | KLIMAN GILBERT H director | Common Stock | 10,000 | $150.28 | $1,502,800 | ||
Option | KLIMAN GILBERT H director | Stock Option (Right to Buy) | 10,000 | $32 | $320,000 | ||
Option | KLIMAN GILBERT H director | Common Stock | 2,000 | $32 | $64,000 |
| Patent |
|---|
Application Filling date: 28 Jan 2022 Issue date: 28 Jul 2022 |
Application Filling date: 3 Dec 2021 Issue date: 28 Jul 2022 |
Application Filling date: 21 Feb 2020 Issue date: 21 Apr 2022 |
Application Filling date: 27 May 2021 Issue date: 20 Jan 2022 |
Grant Design: Implant delivery apparatus Filling date: 4 Nov 2020 Issue date: 14 Dec 2021 |
Grant Filling date: 26 Apr 2019 Issue date: 14 Dec 2021 |
Application Filling date: 2 Jun 2021 Issue date: 9 Dec 2021 |
Application Filling date: 12 Aug 2021 Issue date: 2 Dec 2021 |
Application Filling date: 11 May 2021 Issue date: 25 Nov 2021 |
Application Filling date: 26 Mar 2021 Issue date: 14 Oct 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2024 1 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 21 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 1 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 2 Aug 2023 | Q2 2023 Earnings Call Transcript |
-
What's the price of Glaukos stock today?
One share of Glaukos stock can currently be purchased for approximately $89.
-
When is Glaukos's next earnings date?
Unfortunately, Glaukos's (GKOS) next earnings date is currently unknown.
-
Does Glaukos pay dividends?
No, Glaukos does not pay dividends.
-
How much money does Glaukos make?
Glaukos has a market capitalization of 8.17B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 11.26% to 314.71M US dollars.
-
What is Glaukos's stock symbol?
Glaukos Corporation is traded on the NYSE under the ticker symbol "GKOS".
-
What is Glaukos's primary industry?
Company operates in the Healthcare sector and Medical - Devices industry.
-
How do i buy shares of Glaukos?
Shares of Glaukos can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Glaukos's key executives?
Glaukos's management team includes the following people:
- Mr. Thomas William Burns Chairman, Chief Executive Officer & Pres(age: 64, pay: $1,140,000)
- Mr. Joseph E. Gilliam Chief Financial Officer & Senior Vice President of Corporation Devel.(age: 49, pay: $578,420)
- Mr. Chris M. Calcaterra Chief Operating Officer(age: 65, pay: $553,080)
-
How many employees does Glaukos have?
As Jul 2024, Glaukos employs 907 workers.
-
When Glaukos went public?
Glaukos Corporation is publicly traded company for more then 10 years since IPO on 25 Jun 2015.
-
What is Glaukos's official website?
The official website for Glaukos is glaukos.com.
-
Where are Glaukos's headquarters?
Glaukos is headquartered at 229 Avenida Fabricante, San Clemente, CA.
-
How can i contact Glaukos?
Glaukos's mailing address is 229 Avenida Fabricante, San Clemente, CA and company can be reached via phone at +94 93679600.
-
What is Glaukos stock forecast & price target?
Based on 8 Wall Street analysts` predicted price targets for Glaukos in the last 12 months, the avarage price target is $147.8. The average price target represents a 66.06% change from the last price of $89.
Glaukos company profile:
Glaukos Corporation
glaukos.comExchange:
NYSE
Full time employees:
907
Industry:
Medical - Devices
Sector:
Healthcare
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
229 Avenida Fabricante
San Clemente, CA 92672
San Clemente, CA 92672
CIK: 0001192448
ISIN: US3773221029
CUSIP: 377322102
